Varithena Kit
Product Images NDC 60635-133

Varithena injectable foam is a medication that contains 77.5 mg polidocanol, which is delivered in a 1% polidocanol solution. It comes in a bi-canister and delivers 15 mL of foam for injection, generated through purging instructions in the IFU. The medication is intended for intravenous use only and should not be shaken. It should be stored at or below 86°F (30°C) but should not be refrigerated or frozen. The drug should not come in contact with eyes, and the aerosol canister should be discarded responsibly according to state and local requirements. Varithena is a registered trademark of Provensis Ltd, which is manufactured by Biocompatibles UK Ltd for Provensis Ltd and distributed by Biocompatibles, Inc., all BTG International group companies.*

Varithena is a medication used for intravenous use only. It is an injectable foam containing 77.5 mg of polidocanol, ethanol, disodium hydrogen phosphate dihydrate, potassium dihydrogen phosphate, water for injection, and carbon dioxide. Once activated, it generates 30 mL of foam, which is enough to yield 15 mL of usable foam for injection. It should be stored at or below 86°F (30°C), protected from sunlight, and used within 30 days of activation. It is a registered trademark of Provensis Ltd. Dosage and administration information are available in the Pl and IFU.*

This is a description of a medical product called "Ancillary Pack" designed for use with another medical product "Varithena". It contains three silicone-free syringes, manometer tubing, and compression pads. The pack is manufactured by a company named "P UL NG, PEF" located in West Costonccin with contact details provided. The rest of the text seems to be random characters and is not useful.*

The text seems to be a product description for a medical device called "Convenience Box". The box contains various medical items such as Varithena canister, Varithena Transfer Unit, Ancillary pack, silicone-fresh syringes, compression pads, manometer tubing, and Pl/IFU. It is advised to store the contents at room temperature and not to sterilize them.*

This is a description of a medication called Varithena injectable foam. It is used intravenously only and contains polidocanol 180 mg/18 mL (10 mg/mL). It is a gas under pressure and caution must be taken as it may explode if heated. Each canister generates 90 mL of foam. The medication should be stored in a well-ventilated place at or below 86°F (30°C) and protected from sunlight. For safe usage, the reference FU should be read. The sterile contents should not be resterilized, refrigerated, or frozen. It is advised to avoid contact with the eyes. There is also a 5 mL Aliquot Record.*

Varithena is an injectable foam used for intravenous treatment. It contains 180mg of polidocanol in one canister of 18mL of solution and carbon dioxide and another canister of oxygen. Once activated, Varithena generates 90mL of foam, enough for 45mL of usable foam for injection. The drug is manufactured by Biocompatibles UK Ltd for Provensis Ltd, distributed by Biocompatibles, Inc, and is available in a Bi-canister. Specific instructions for dosage, administration, storage, and discarding the aerosol canister are present, and it is essential to discard the contents if damaged.*

Varithena is a treatment manufactured by BTG Hemerica which helps to treat venous insufficient. The contents of the canister include 1% polidocanol solution, ethanol, and water for injection. Varithena is injected via foam with each mL of Varithena Injectable foam contains 1.3mg of polidocanol. The canister generates 90mL of foam which is enough to yield 45mL of usable foam. It is important to discard the canister if contents are damaged or contact with the eyes should be avoided.*

This text describes the Administration Pack for use with any Varithena Bi-Canister Box, which contains polidocanol injectable foam. A new box must be used for each patient and the pack contains silicone-free syringes, Varithena Transfer Unit, compression pads and manometer tubing. The provided dosage and administration information should be read before use. The sterile contents should not be sterilized and should be stored below 86°F (30°C).*